Expert review of pharmacoeconomics & outcomes research · 2026
Economic and humanistic burden of chronic liver diseases in the United States.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khalid Javeria, Huang Yinan, Aparasu Rajender R
Аннотация
BACKGROUND: Little is known about the healthcare burden of Chronic liver disease (CLD) post-introduction of newer antiviral therapies for hepatitis. Therefore, this national study examined healthcare expenditures, productivity loss, and health-related quality of life (HRQoL) of patients with CLD.
METHODS: This retrospective, cross-sectional analysis utilized the 2014-2021 Medical Expenditure Panel Survey involving patients with CLD ≥18 years. Two-part model was employed to estimate incremental direct medical costs. Multivariable models were used to evaluate missed workdays and HRQoL.
RESULTS: Annually, 1.63 million patients (95%CI=1.47-1.81) were diagnosed with CLD, with a prevalence of 0.59%. The mean annual incremental healthcare expenditure attributable to CLD was $11,711 (95%CI=$6,867.048-$16,555.36). Patients with CLD have 0.12 (95%CI=0.09-0.15) more missed workdays, translating into a national productivity loss of $51.6 million. Additionally, HRQoL was significantly lower in CLD patients, with mean differences of -3.72 (95%CI = -4.6 to -2.84) for physical component summary score and -1.83 (95%CI = -2.68 to -0.97) fore mental component summary score.
CONCLUSIONS: CLD was associated with a significant healthcare burden, as evidenced by healthcare expenditure, productivity loss, and HRQoL. Therefore, concerted efforts are needed to improve the prevention and management of CLD to reduce the disease burden.
METHODS: This retrospective, cross-sectional analysis utilized the 2014-2021 Medical Expenditure Panel Survey involving patients with CLD ≥18 years. Two-part model was employed to estimate incremental direct medical costs. Multivariable models were used to evaluate missed workdays and HRQoL.
RESULTS: Annually, 1.63 million patients (95%CI=1.47-1.81) were diagnosed with CLD, with a prevalence of 0.59%. The mean annual incremental healthcare expenditure attributable to CLD was $11,711 (95%CI=$6,867.048-$16,555.36). Patients with CLD have 0.12 (95%CI=0.09-0.15) more missed workdays, translating into a national productivity loss of $51.6 million. Additionally, HRQoL was significantly lower in CLD patients, with mean differences of -3.72 (95%CI = -4.6 to -2.84) for physical component summary score and -1.83 (95%CI = -2.68 to -0.97) fore mental component summary score.
CONCLUSIONS: CLD was associated with a significant healthcare burden, as evidenced by healthcare expenditure, productivity loss, and HRQoL. Therefore, concerted efforts are needed to improve the prevention and management of CLD to reduce the disease burden.